Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02511782 · ClinicalTrials.gov registry record · NA
Transdermal Patch to Monitor Inflammatory Biomarkers of GVHD
A NA study, sponsored by Children's Hospital Medical Center, Cincinnati.
- Completed
- Registry status
- NA
- Development phase
- 63
- Enrollment target
NCT02511782: Completed NA study, sponsored by Children's Hospital Medical Center, Cincinnati.
NCT02511782 is a NA study that has completed, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 63 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02511782, a NA study, has completed, sponsored by Children's Hospital Medical Center, Cincinnati.
- COMPLETED
- Registry status
- NA
- Development phase
- 63 participants
- Enrollment target
Study Summary
The aim of this study is to measure local inflammatory responses in patients undergoing an allogeneic stem cell transplant and attempt to define any set of biomarkers that are significantly altered in acute or chronic skin graft versus host disease.
Primary Outcome
D-sqaume epidermal discs were used to assess CXCL10 levels from skin.
Interventions
- DEVICE D-SQUAME Skin Sampling Discs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2012-02 |
| Est. Completion | 2014-10 |
| Phase | NA |
What the finished NCT02511782 record still lists
NCT02511782 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which D-SQUAME Skin Sampling Discs is the first listed.
NCT02511782 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02511782 about?
NCT02511782 is a clinical study titled "Transdermal Patch to Monitor Inflammatory Biomarkers of GVHD". The aim of this study is to measure local inflammatory responses in patients undergoing an allogeneic stem cell transplant and attempt to define any set of biomarkers that are significantly altered in acute or chronic skin graft versus host disease.
What is the current status of trial NCT02511782?
This trial is currently completed. It is a NA study. The enrollment target is 63 participants. The study started on 2012-02. Estimated completion is 2014-10.
What interventions are being tested in trial NCT02511782?
The interventions under investigation include: D-SQUAME Skin Sampling Discs (DEVICE).
Who is sponsoring clinical trial NCT02511782?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02511782's enrollment target sits among peer trials
63 1157th of 2000 higher than 844 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia